These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
450 related articles for article (PubMed ID: 31127385)
1. PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study. Savic S; Berezowska S; Eppenberger-Castori S; Cathomas G; Diebold J; Fleischmann A; Jochum W; Komminoth P; McKee T; Letovanec I; Jasarevic Z; Rössle M; Singer G; von Gunten M; Zettl A; Zweifel R; Soltermann A; Bubendorf L Virchows Arch; 2019 Jul; 475(1):67-76. PubMed ID: 31127385 [TBL] [Abstract][Full Text] [Related]
2. Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms. Ilie M; Khambata-Ford S; Copie-Bergman C; Huang L; Juco J; Hofman V; Hofman P PLoS One; 2017; 12(8):e0183023. PubMed ID: 28797130 [TBL] [Abstract][Full Text] [Related]
3. PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs: An Interclone Evaluation by Differently Trained Pathologists. Munari E; Rossi G; Zamboni G; Lunardi G; Marconi M; Sommaggio M; Netto GJ; Hoque MO; Brunelli M; Martignoni G; Haffner MC; Moretta F; Pegoraro MC; Cavazza A; Samogin G; Furlan V; Mariotti FR; Vacca P; Moretta L; Bogina G Am J Surg Pathol; 2018 Oct; 42(10):1384-1389. PubMed ID: 29901568 [TBL] [Abstract][Full Text] [Related]
4. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors. Marchetti A; Barberis M; Franco R; De Luca G; Pace MV; Staibano S; Volante M; Buttitta F; Guerini-Rocco E; Righi L; D'antuono T; Scagliotti GV; Pinto C; De Rosa G; Papotti M J Thorac Oncol; 2017 Nov; 12(11):1654-1663. PubMed ID: 28818609 [TBL] [Abstract][Full Text] [Related]
5. Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer. Adam J; Le Stang N; Rouquette I; Cazes A; Badoual C; Pinot-Roussel H; Tixier L; Danel C; Damiola F; Damotte D; Penault-Llorca F; Lantuéjoul S Ann Oncol; 2018 Apr; 29(4):953-958. PubMed ID: 29351573 [TBL] [Abstract][Full Text] [Related]
6. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372 [TBL] [Abstract][Full Text] [Related]
7. A Harmonization Study for the Use of 22C3 PD-L1 Immunohistochemical Staining on Ventana's Platform. Neuman T; London M; Kania-Almog J; Litvin A; Zohar Y; Fridel L; Sandbank J; Barshak I; Vainer GW J Thorac Oncol; 2016 Nov; 11(11):1863-1868. PubMed ID: 27664534 [TBL] [Abstract][Full Text] [Related]
8. Comparison of PD-L1 Assays in Non-small Cell Lung Cancer: 22C3 pharmDx and SP263. Fujimoto D; Yamashita D; Fukuoka J; Kitamura Y; Hosoya K; Kawachi H; Sato Y; Nagata K; Nakagawa A; Tachikawa R; Date N; Sakanoue I; Hamakawa H; Takahashi Y; Tomii K Anticancer Res; 2018 Dec; 38(12):6891-6895. PubMed ID: 30504406 [TBL] [Abstract][Full Text] [Related]
9. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients. Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536 [TBL] [Abstract][Full Text] [Related]
10. Comparability of laboratory-developed and commercial PD-L1 assays in non-small cell lung carcinoma. Naso JR; Wang G; Banyi N; Derakhshan F; Shokoohi A; Ho C; Zhou C; Ionescu DN Ann Diagn Pathol; 2021 Feb; 50():151590. PubMed ID: 33157383 [TBL] [Abstract][Full Text] [Related]
11. Validation of PD-L1 clone 22C3 immunohistochemical stain on two Ventana DISCOVERY autostainer models: detailed protocols, test performance characteristics, and interobserver reliability analyses. Basu A; Chiriboga L; Narula N; Zhou F; Moreira AL J Histotechnol; 2020 Dec; 43(4):174-181. PubMed ID: 33245263 [TBL] [Abstract][Full Text] [Related]
12. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer. Büttner R; Gosney JR; Skov BG; Adam J; Motoi N; Bloom KJ; Dietel M; Longshore JW; López-Ríos F; Penault-Llorca F; Viale G; Wotherspoon AC; Kerr KM; Tsao MS J Clin Oncol; 2017 Dec; 35(34):3867-3876. PubMed ID: 29053400 [TBL] [Abstract][Full Text] [Related]
13. Indirect Clinical Validation of a Programmed Death-Ligand 1 Laboratory-Developed Test for Gastric/Gastroesophageal Junction Adenocarcinoma with 22C3 Antibody Concentrate. Kim JM; Kim B; Kim E; Jang M; Cho JH; Lee HS; Kwak Y; Huang L; Krishnan R; Bai SY; Mounawar M; Kim KM Mol Diagn Ther; 2022 Nov; 26(6):679-688. PubMed ID: 36125657 [TBL] [Abstract][Full Text] [Related]
14. Comparison of PD-L1 Expression Using 2 Validated PD-L1 IHC 22C3 pharmDx Methods in Non-Small Cell Lung Cancer in a Routine Hospital Setting. Skov BG Appl Immunohistochem Mol Morphol; 2021 Jan; 29(1):49-55. PubMed ID: 31913160 [TBL] [Abstract][Full Text] [Related]
15. Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. Eckstein M; Erben P; Kriegmair MC; Worst TS; Weiß CA; Wirtz RM; Wach S; Stoehr R; Sikic D; Geppert CI; Weyerer V; Bertz S; Breyer J; Otto W; Keck B; Burger M; Taubert H; Weichert W; Wullich B; Bolenz C; Hartmann A; Erlmeier F Eur J Cancer; 2019 Jan; 106():234-243. PubMed ID: 30528808 [TBL] [Abstract][Full Text] [Related]
16. Comparison of continuous measures across diagnostic PD-L1 assays in non-small cell lung cancer using automated image analysis. Widmaier M; Wiestler T; Walker J; Barker C; Scott ML; Sekhavati F; Budco A; Schneider K; Segerer FJ; Steele K; Rebelatto MC Mod Pathol; 2020 Mar; 33(3):380-390. PubMed ID: 31527709 [TBL] [Abstract][Full Text] [Related]
17. PD-L1 immunohistochemistry in non-small-cell lung cancer: unraveling differences in staining concordance and interpretation. Keppens C; Dequeker EM; Pauwels P; Ryska A; 't Hart N; von der Thüsen JH Virchows Arch; 2021 May; 478(5):827-839. PubMed ID: 33275169 [TBL] [Abstract][Full Text] [Related]
18. Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma. Zajac M; Scott M; Ratcliffe M; Scorer P; Barker C; Al-Masri H; Rebelatto MC; Walker J Diagn Pathol; 2019 Sep; 14(1):99. PubMed ID: 31477145 [TBL] [Abstract][Full Text] [Related]
19. PD-L1 expression in non-small cell lung cancer: evaluation of the diagnostic accuracy of a laboratory-developed test using clone E1L3N in comparison with 22C3 and SP263 assays. Munari E; Zamboni G; Lunardi G; Marconi M; Brunelli M; Martignoni G; Netto GJ; Quatrini L; Vacca P; Moretta L; Bogina G Hum Pathol; 2019 Aug; 90():54-59. PubMed ID: 31121194 [TBL] [Abstract][Full Text] [Related]
20. PD-L1 testing in metastatic triple-negative breast cancer: Interobserver and interplatform reproducibility of CE-IVD assays for CPS and IC scores. Ivanova M; Frascarelli C; Cerbelli B; Pignataro MG; Pernazza A; Venetis K; Sajjadi E; Criscitiello C; Curigliano G; Guerini-Rocco E; Graziano P; Martini M; d'Amati G; Fusco N Hum Pathol; 2024 Feb; 144():22-27. PubMed ID: 38278450 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]